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Background: Albendazole (ABZ) is a microtubule-targeting anthelmintic with a remarkable activity against a variety
of human cancer cells. In this study, we examined if the antitumor activity of ABZ could be enhanced by its
combination with other microtubule-binding agents.
Methods: The interactions between ABZ and microtubule-binding agents, paclitaxel, vinblastine, colchicine, and
2-methoxyestradiol were characterized using median effect analysis method in HCT-116 colorectal cancer cells
and DU145 prostate cancer cell line. The mechanism underlying the synergistic interaction related to tubulin
polymerization and apoptosis was then investigated. Finally, the effect of the combination therapy on the
survival of HCT-116 tumor-bearing nude mice was evaluated.
Results: Among the tested drugs, a synergistic anti-proliferative effect was observed with the combination of
low concentrations of ABZ plus colchicine and ABZ plus 2-methoxyestradiol (2ME). Exploring the mechanism of
the interaction between ABZ and 2ME revealed that the combination therapy synergistically activated the
extrinsic pathway of apoptosis. Consistent with in vitro results, the combination of low concentration of ABZ
with 2ME prolonged the survival of mice-bearing HCT-116 tumors. High concentration of ABZ in combination
with 2ME, however, proved to be less effective than ABZ alone.
Conclusions: The combination of low doses of ABZ and 2ME has shown promising results in our pre-clinical
model. Additionally, the finding that the combination of two microtubule-binding agents that share the same
binding site can act synergistically may lead to the development of new therapeutic strategies in cancer
treatment.
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Combination therapy is the main approach in the treat-
ment of various types of malignancies. The aims of using
drug combinations are to increase efficacy, to reduce the
dose and therefore, the toxicity, and to minimize or
delay drug resistance [1].
Microtubule-targeting agents (MTAs) are among the
most promising classes of the drugs in cancer therapy. Over
the past decades, several MTAs have been discovered and
developed into the established anticancer agents in the* Correspondence: s3199267@unsw.edu.au
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reproduction in any medium, provided the orclinic. Traditionally, MTAs are classified into two major
groups. One group are microtubule-stabilizing agents
which polymerize microtubules and increase microtubule
polymer mass. Second group, known as microtubule-
destabilizing agents, inhibit polymerization of microtubules
and reduce microtubule polymer mass [2]. Notwithstand-
ing, at the clinically relevant concentrations, MTAs sup-
press microtubule dynamics, leading to the impairment of
the metaphase to anaphase transition, and ultimately apop-
totic cell death.
Given the fact that MTAs bind to different sites of tubu-
lin, their combination with each other has potential to im-
prove their antitumor activity. Additionally, combination
therapy with MTAs may also reduce the toxicity associatedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(MTD). Currently, most chemotherapeutic drugs are ad-
ministered as bolus injection at their MTDs followed by a
rest period, allowing tumor cell re-population between
successive chemotherapy [3]. Therefore, combining low
doses of chemotherapeutic agents at close regular intervals
may enhance efficacy while reducing the toxicity.
Albendazole (ABZ) is a microtubule-targeting agent from
benzimidazole group of compounds. It has previously been
shown that ABZ has a remarkable activity against a number
of cancer cells [4,5]. In preclinical studies, ABZ suppressed
the growth of solid tumors as well as the formation of
malignant ascites derived from ovarian cancer [6]. Benz-
imidazoles have been shown to bind to the colchicine-
binding site of tubulin and inhibit the polymerization of
microtubules [7,8].
The aim of this study was to develop a novel thera-
peutic strategy using combination therapy. To this end,
combination of ABZ with paclitaxel (PTX), vinblastine
(VBL), and colchicine (CLC), as the representative drugs
that interact with the established binding sites on tubu-
lin was evaluated. Our findings showed that ABZ and
CLC exhibited a synergistic anti-proliferative effect on
HCT-116 and DU145 cell lines. Since CLC is not used
in cancer therapy due to its toxicity [9], the interaction
between ABZ and 2-methoxyestradiol (2ME), a related
and a structurally similar compound to CLC was tested
and found to be synergistic with ABZ. The mechanism
underlying the synergistic interaction between ABZ and
2ME was then investigated and the antitumor effect of
the combination therapy in mice bearing colorectal can-
cer xenograft was evaluated.
Methods
Chemicals
ABZ, 2ME, CLC, VBL, PTX, Sulforhodamine B, and
carboxymethyl cellulose (CMC) were purchased from
Sigma (Sydney, Australia), and hdroxypropyl-β-cyclodextrin
(HPβCD) was from Cyclodextrin Technologies Develop-
ment, Inc. (CTD; Florida, USA).
Cell culture
The human colorectal cancer cell line HCT-116 and the
prostate cancer cell line DU145 were originally obtained
from ATCC. Both cell lines maintained in RPMI-1640
supplemented with 10% heat-inactivated fetal bovine
serum (FBS), 50 units/ml penicillin, and 50 units/ml
streptomycin. The cells were incubated at 37°C in a 5%
CO2 humidified incubator.
Cytotoxicity assay
HCT-116 and DU145 cells were seeded in 96-well plates
at a density of 2500 and 3500 cells/well, respectively.
After 24 hours incubation, the cells were treated withsingle agents and their combination for 72 hours. At the
end of the treatment period, cell growth inhibition was
assessed using the sulfothodamine B assay (SRB) as de-
scribed previously [10].
To evaluate the effect of drug sequence in combination
therapy, cells were treated with ABZ for 24 hours followed
by 2ME for a further 48 hours or vice versa. In order to
provide a constant experimental condition, concurrent
treatment with ABZ and 2ME was performed alongside
the sequential treatment and similarly, drug-containing
medium was replaced with fresh drug after 24 hours.
Drug interaction analysis
The interaction between the drugs in combination was de-
termined by the median effect analysis using CalcuSyn soft-
ware (Biosoft, Cambridge, UK), which calculates the
combination index (CI) based on drug doses and cell sur-
vival. A CI less than 1 indicates synergism, equal to 1 indi-
cates additivity, and greater than 1 indicates antagonism.
Tubulin polymerization assay
HCT-116 cells were plated at a density of 5 × 105 cells in
six-well plates and allowed to attach overnight. Cells were
then treated with ABZ, 2ME, and their combination. After
24 hours incubation with the drugs, a quantitative tubulin
polymerization assay was performed as described previ-
ously [11].
Western blotting
To prepare the whole cell lysate from cells, HCT-116 cells
were grown to 60-70% confluency and treated with ABZ,
2ME or their combination for 24 hours. Cells were then
lysed and centrifuged at 10,000 g for 10 minutes. To gen-
erate the lysate from tumor tissues, 100 mg tissue was
lysed and homogenized in RIPA buffer (Sigma, Australia)
containing 10% protease inhibitor cocktail. The samples
were then centrifuged at 10,000g for 10 minutes and the
protein content in supernatant was quantified using
Bradford method (Bio-Rad protein assay kit, Bio-Rad,
USA). Fifty micrograms protein were resolved on 12% gels
and electrophoresed for 2 hours at 85V. Proteins were
then transferred to Polyvinylidene Fluoride (PVDF) mem-
branes and the membranes were incubated with the
primary antibody for one hour at room temperature
(Vascular Endothelial Growth Factor [VEGF] and P53,
1:200 dilution, Santa Cruz, USA) or overnight at 4°C
(Death Receptor 5, [DR5] 1:400, R&D System, USA)
followed by one-hour incubation with HRP-conjugated
secondary antibodies (1:1000 dilution, Cell Signaling,
USA). The bands were visualized by an enhanced chemilu-
minescence detection kit (GE Healthcare, Australia). The
blots were then stripped using Seppro western blot strip-
ping buffer (Sigma, Australia) and re-probed with β-actin
(1:1000 dilution, Sigma, Australia).
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To assess the activation of caspase 3, caspase 8, and
caspase 9 in HCT-116 cells, the cells were incubated with
ABZ, 2ME and their combination for 24 hours. The
caspase activity was determined using caspase colorimetric
assay kits according to the manufacturer’s instructions
(R&D system, USA).
Mice
Ten-week-old female BALB/c nude mice obtained from
The Animal Resources Centre (Perth, Australia) and
housed in a pathogen free environment for one week before
the commencement of the experiments. All experiments
were conducted according to the protocols approved by the
Animal Experimentation Ethics Committee of the Univer-
sity of New South Wales.
Drug preparation for in vivo study
ABZ was solubilized in 25% HPβCD (w/v in dH2O) [12].
2ME was solubilized in 25% HPβCD (w/v in dH2O)
containing 0.5% (w/v) carboxymethyl cellulose (CMC) at
a concentration of 1 mg/ml. After 3 days storage at 4°C,
2ME was dissolved and no precipitation was observed.
Tumor growth study
Prior to the in vivo experiment, a pilot study using two
groups of four animals was carried out to evaluate the pos-
sible toxicity of simultaneous administration of ABZ and
2ME. Group 1 received the combination of ABZ and 2ME
and group 2 were given the combination of the vehicle of
the two agents. Following administration, mice in both
groups showed an evidence of acute toxicity. Therefore, in
the subsequent study, ABZ and 2ME were administered
sequentially with ABZ preceding 2ME.
HCT-116 cells were harvested using 1% trypsin-EDTA
and a single-cell suspension of 2×106 cells in 0.1 ml of
matrigel was injected subcutaneously into the hind leg
of the animals. When the tumors had grown to approxi-
mately 100 mm3, the mice were randomized into six
groups of 8–9 animals and treated intraperitoneally as
follows: (1) 50 mg/kg ABZ, (2) 25 mg/kg ABZ, (3) 25
mg/kg 2ME, (4) 50 mg/kg ABZ + 25 mg/kg 2ME, (5) 25
mg/kg ABZ + 25 mg/kg 2ME, and (6) vehicle control.
For combination treatment, ABZ was administered on
day 1 followed by 2ME 24 h later (day 2). To assess the
effect of individual drugs, the animals were treated with
ABZ on day 1 and the vehicle of 2ME on day 2, or the
vehicle of ABZ on day 1 and 2ME on day 2. Control ani-
mals received vehicle alone (ABZ vehicle on day 1 and
2ME vehicle on day 2). Tumor volume was measured
every three days using the formula: (shortest diameter)2
x longest diameter × 0.5. When the tumor size reached
1000 mm3, mice were euthanized by an overdose of
Lethabarb (Virbac, Australia).Immunohistochemistry
Immunohistochemistry analysis was performed as de-
scribed previously [13]. For all experiments, multiple sec-
tions obtained from each treatment group and the average
number of positive cells/area was calculated from 5 fields
of each section.
Frozen sections (5 μm) were stained with CD31 (BD
Bioscience, Australia) to visualize microvessels. For detec-
tion of apoptosis and proliferating tumor cells, paraffin-
embedded sections (5 μm) were used. Apoptotic cells
in tumor sections were stained using the terminal
deoxynucleotidyl transferase–mediated dUTP nick end la-
beling (TUNEL) detection system (Roche) and proliferat-
ing tumor cells were detected by Ki67 staining (DAKO,
Australia). Analysis of CD31-stained areas and TUNEL-
positive cells was carried out using NIH ImageJ software
(version 1.44; National Institutes of Health, Bethesda,
MD) and Ki67-positive cells were quantified manually.
VEGF ELISA assay
The concentration of VEGF in mice plasma was deter-
mined using Human VEGF Quantikine ELISA Kit (R&D
System) according to the manufacturer’s instructions.Statistical analysis
Data are presented as the mean ± SEM. All statistical
analyses were performed using the GraphPad Prism soft-
ware package version 5.0 (GraphPad Software Inc., San
Diego, CA, USA). The survival days of animals were de-
termined using the Kaplan-Meier plots and compared by
the log-rank test. P values < 0.05 were considered to be
significant. Differences between the groups were evalu-
ated using Student’s t-test and one-way ANOVA.Results
ABZ synergizes with colchicine
In both HCT-116 and DU145 cells, the combination of
ABZ and PTX were antagonistic, as CI values were
consistently above 1 (Figure 1A and 1B). Likewise, an-
tagonism was observed when ABZ combined with VBL,
with CI values above 1 at all tested concentrations
(Figure 1C and 1D).
Conversely, at lower concentrations (below 5 μM),
ABZ was synergistic with CLC. However, as the concen-
tration of ABZ increased, the interaction changed from
nearly additive (5 μM ABZ) to antagonism (10 μM ABZ)
(Figure 1E and 1F). Similar to CLC, the combination of
ABZ and 2ME resulted in synergism at doses below 5
μM ABZ, as the combination index was consistently less
than 1. However, the combination of 5 μM and 10 μM
ABZ with 2ME led to additivity and antagonism, re-
spectively (Figure 1G and 1H).
Figure 1 The effect of ABZ in combination with PTX (A,B), VBL (C,D), CLC (E,F), and 2ME (G,H) on HCT-116 (left panel) and DU145 cells
(right panel). Cell viability was assessed by the SRB assay after 72 hours of simultaneous incubation with the drugs. Data were analyzed with
Calcusyn software. CI < 1 indicates synergism, CI >1 indicates antagonism and CI = 1 shows additive effect.
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dependent and schedule-dependent
We next evaluated the effect of drug sequencing on the
synergism between ABZ and 2ME in HCT-116 cell line.
As shown in Figure 2B, pre-treatment with ABZ resulted
in higher CI values compared with simultaneous treat-
ment (Figure 2A). Nevertheless, at concentrations below
5 μM ABZ, the interaction remained synergistic. As
the concentration of ABZ increased, the interaction
changed from synergism to antagonism. Pre-treatment
with 2ME resulted in antagonism throughout the range of
tested 2ME concentrations (Figure 2C). Indeed, as the
concentration of 2ME increased, the antagonism was
more pronounced.Figure 2 Cytotoxic interaction between ABZ and 2ME. A, HCT-
116 cells were exposed to ABZ and 2ME for 72 hours simultaneously
or B, treated with ABZ for 24 hours followed by additional 48 hours
treatment with 2ME or C, treated with 2ME for 24 hours followed by
additional 48 hours treatment with ABZ. CI < 1 indicates synergism,
CI >1 indicates antagonism and CI = 1 shows additive effect.Mechanism of synergistic interaction between ABZ and
2ME
In the studies, the mechanism underlying the synergistic
interaction between ABZ and 2ME was evaluated. To this
end, the effect of the combination therapy on tubulin
polymerization and apoptosis was investigated. The opti-
mal concentrations of ABZ and 2ME in combination were
determined in a 24-hours growth inhibition assay, and low
concentrations, which had a minimal effect as single
agents, were chosen.
Combination of ABZ with 2ME has no synergistic effect
on tubulin polymerization
To examine whether ABZ and 2ME synergistically
depolymerize tubulin, a quantitative tubulin polymerization
assay on HCT-116 cells was performed. In this assay,
polymerized tubulin remains in the pellet after centrifuga-
tion, as it is not soluble in hypotonic buffer. In contrast,
depolymerized or soluble tubulin remains in supernatant.
Therefore, tubulin-depolymerizing agents increase the level
of soluble tubulin in the supernatant whereas tubulin-
polymerizing agents increase the insoluble tubulin in the
pellet [14]. Treatment of HCT-116 cells with ABZ at the
concentrations of 0.1 μM and 0.25 μM, and with 2ME
at the concentration of 0.75 μM as single agents had
no effect on tubulin polymerization compared with control
(p > 0.05). Similarly, combination therapy did not increase
tubulin depolymerization compared with the single agent
treatment (Figure 3A).Combination of ABZ and 2ME induces apoptotic cell
death in HCT-116 cells through extrinsic pathway
To investigate whether the combination of ABZ and 2ME
activated caspase-dependent apoptotic pathway, caspase
8 and caspase 9 activities, as initiators of extrinsic and
intrinsic pathway of apoptosis were evaluated. In addition,
the activity of the downstream effector, caspase 3 was
also assessed.
As depicted in Figure 3B, treatment with ABZ, 2ME
and ABZ plus 2ME resulted in the activation of caspase-
8 and caspase-3, which was evidenced after 16 hours.
In cells that were treated with the combination of ABZ
and 2ME, the activity of caspase-8 and caspase-3 was
significantly higher in comparison with the single agents
(p < 0.05). In contrast, neither the single agents nor their
combination altered the activity of caspase-9, suggesting
that the drug-induced apoptosis was not mediated
through the intrinsic pathway (Figure 3B).
To further investigate the signaling events involved in the
apoptosis, the effect of the combination treatment on DR5
protein levels was determined using western blot analysis.
As shown in Figure 3C, ABZ and 2ME significantly
upregulated the expression of DR5 compared with the
Figure 3 Mechanism of interaction between ABZ and 2ME. A, Effect of combination therapy on tubulin polymerization. Cells were treated with
the indicated concentrations of ABZ, 2ME, and their combination for 24 hours The percentage of polymerized tubulin was determined by dividing the
densitometric value of polymerized tubulin by the total tubulin content. The blot is a representative blot from four experiments. B, Effect of ABZ and
2ME on caspase activation. HCT-116 cells were incubated with vehicle, ABZ, 2ME, and their combination at indicated concentrations for 4, 8, 16, 24
hours. Caspase activity was determined by caspase substrates labeled with p-nitroaniline (pNA) using colorimetic assay. The data represent the mean
values for duplicate measurements from three experiments. C, Effect of ABZ, 2ME and their combination on DR5 and P53 protein expression. HCT-116
cells were treated with vehicle, ABZ, 2ME, and ABZ plus 2ME at indicated concentrations for 24 hours. Cells were then lysed and subjected to western
blot analysis. β-actin was used as a control for equal protein loading. The bar graphs represent the mean protein expression of three individual
experiments, with error bars showing SEM. (*P < 0.05 compared with single agents).
Ehteda et al. BMC Cancer 2013, 13:86 Page 6 of 13
http://www.biomedcentral.com/1471-2407/13/86vehicle-treated cells (p < 0.05). In addition, the combination
of the two drugs further increased the levels of DR5 protein
compared with the single agents (p < 0.05). These results
suggest that the activation of caspase-8 is at least in part,
dependent on death receptor signaling.HCT-116 cells harbor wild-type p53. Therefore, it was
hypothesized that the upregulation of DR5 could be a
consequence of p53-induced growth arrest. To test this
hypothesis, the level of p53 protein was determined by
western blotting. As shown in Figure 3C, no significant
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and treated cells, suggesting that the drug-induced cell
kill, as well as upregulation of DR5 receptor was inde-
pendent from p53.Combination of low doses of ABZ plus 2ME delays the
tumor growth and prolongs the survival of mice-bearing
HCT-116 xenograft
Treatment with 50 mg/kg ABZ as a single agent signifi-
cantly prolonged the survival of mice compared with
vehicle-treated group, with a median survival of 41.5 days
for ABZ and 23 days for control mice (p = 0.001) (Figure 4).
Likewise, 25 mg/kg ABZ as a single agent significantly de-
layed the tumor growth compared with the vehicle-treated
group, with a median survival 31 days (p = 0.044). In con-
trast, 25 mg/kg 2ME alone led to a modest, but not statis-
tically significant improvement in survival (median = 29.5),
compared with control mice (p = 0.103).
Similarly, no survival benefit was observed in animals
that were treated with the combination of 50 mg/kg ABZ
and 25 mg/kg 2ME in comparison with vehicle-treated an-
imals (median survival = 29.5 days, p = 0.111). In fact, com-
bination therapy exhibited an antagonistic response, as the
median survival of the animals which were treated with
the combination of 50 mg/kg ABZ and 2ME was signifi-
cantly less than the survival of mice that were treated with
ABZ as a single agent (p = 0.096) (Figure 4A). These re-
sults were consistent with in vitro drug interaction analysis
where the combination of 2ME with high concentrations
of ABZ resulted in an antagonistic effect on the prolifera-
tion of HCT-116 and DU145 cells (Figure 2).
In contrast, the combination of 25 mg/kg ABZ with
2ME statistically significantly prolonged the survival of
animals (median = 40.5 days) in comparison with control
group (p = 0.0019). In addition, the combination of 25
mg/kg ABZ with 2ME was substantially superior to ABZ
and 2ME alone (p = 0.015 and p = 0.005, respectively)
(Figure 4B).Combination of ABZ and 2ME reduces the proliferation
rate and microvessel density and induces apoptosis in
HCT-116 tumor
To assess the effect of the combination therapy on the sup-
pression of tumor cell proliferation, immunohistochemistry
analysis of Ki67 on tumor sections from all treatment
groups was performed (Figure 5). While both 50 mg/kg
and 25 mg/kg ABZ as single agents significantly reduced
the proliferation rate of the tumor cells, 2ME had no effect
on ki-67 rate. Combination therapy with 50 mg/kg ABZ
and 2ME resulted in a significant decrease in the tumor
proliferation rate in comparison with the control (p < 0.05).
However, 50 mg/kg ABZ as a single agent was moreeffective in the suppression of the proliferation rate than
the combination therapy (p < 0.05). Conversely, combin-
ation of 25 mg/kg ABZ with 2ME led to a statistically sig-
nificant reduction in the proliferation rate, compared with
vehicle-treated mice and the mice that received ABZ and
2ME as single agents (p < 0.05). These results suggest that
the increase in survival rate of animals that were treated
with the combination of 25 mg/kg ABZ and 2ME was, at
least in part, due to the suppression of the tumor
cells proliferation.
To examine whether the inhibition of tumor growth
was associated with a reduction in the vascularization
level of the tumors, the expression of CD31, an endothe-
lial cell marker was evaluated using immunohistochem-
istry (Figure 5). Animals that were treated with single
agents had a significant decrease in the tumoral CD31
compared with the mice that received no treatment
(p < 0.05). Similarly, tumor sections from the mice that
received the combination of 50 mg/kg ABZ with 2ME
displayed a significant reduction in CD31 antigen in
comparison with vehicle-treated group (p < 0.05). How-
ever, 50 mg/kg ABZ as a single agent was more effective
in reducing CD31 levels compared with the combination
therapy (p < 0.05). Additionally, no differences in the
degree of vascularization were observed in combination-
treated group in comparison with 2ME-treated group
(P > 0.05). In contrast, in the animals that received the
combination of 25 mg/kg ABZ and 2ME, suppression of
angiogenesis was more pronounced than in mice that
were treated with the single agents (p < 0.05). These
results imply that the survival benefit of animals that were
given the combination of 25 mg/kg ABZ and 2ME was in
part, due to the suppression of angiogenesis.
Finally, TUNEL assay was performed to determine
whether ABZ, 2ME and their combination induce apop-
totic cell death in tumor cells (Figure 5). TUNEL-positive
cells in tumors which were treated with ABZ alone at both
25 and 50 mg/kg concentrations were significantly higher
than vehicle-treated tumors (p < 0.05). In contrast, the
number of TUNEL-positive cells in the animals that were
treated with 2ME was not significantly different from
those that received no treatment (p > 0.05). Combination
therapy with 50 mg/kg ABZ and 2ME was significantly less
effective in inducing apoptosis in tumor cells, compared
with the effect of 50 mg/kg ABZ as a single agent
(p < 0.05). In contrast, in the animals that received the
combination of 25 mg/kg ABZ and 2ME, TUNEL-positive
cells were markedly higher than those that were treated
with the single agents (p < 0.05).
These results suggest that in addition to the suppression
of the proliferation rate and angiogenesis, induction of
apoptosis was also contributed to the survival benefit of
the animals that were treated with the combination of 25
mg/kg ABZ and 2ME.
Figure 4 In vivo response of HCT-116 xenografts to ABZ, 2ME and ABZ plus 2ME. Mice were inoculated with 2x106 HCT-116 cells. When
the tumor size reached approximately 100 mm3, animals were randomized into six treatment groups and treated with the vehicle control,
25 mg/kg ABZ, 50 mg/kg ABZ, 25 mg/kg 2ME, 50 mg/kg ABZ plus 2ME, and 25 mg/kg ABZ plus 2ME. To assess the effect of individual drugs,
animals were treated with ABZ on day 1 and the vehicle of 2ME on day 2, or ABZ vehicle on day 1 and 2ME on day 2. Combination therapy
groups received ABZ on day 1 followed by 2ME 24 h later (day 2). Control animals received vehicle alone. Mice were euthanized when the tumor
size reached 1000 mm3. (A) Effect of the combination of high concentration of ABZ (50 mg/kg) plus 2ME on the survival of the animals (B) Effect
of the combination of low dose of ABZ (25 mg/kg) plus 2ME on the survival of the animals (C) Median survival analysis. The median survival of
mice in all treatment groups was calculated using Kaplan-Meier statistics. The log-rank P-value is the comparison between each treatment group
with untreated mice.
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and plasma of mice-bearing HCT-116 tumor
To further explore the mechanism underlying the inter-
action between ABZ and 2ME, tumors and plasma sam-
ples of the animals from each treatment group were
analyzed for VEGF expression.
As shown in Figure 6A, 50 mg/kg ABZ significantly re-
duced the expression of VEGF in tumor (p < 0.0001). In
contrast, 25 mg/kg ABZ and 2ME as single agents had nosignificant effect on VEGF expression (p > 0.05). Consist-
ent with the results from immunohistochemistry, the com-
bination of 50 mg/kg ABZ and 2ME was less effective
than 50 mg/kg ABZ as a single agent. Conversely, 25 mg/
kg ABZ combined with 2ME markedly suppressed VEGF
expression (p < 0.0001).
As depicted in Figure 6B, both 25 mg/kg ABZ and 2ME
failed to reduce VEGF levels in plasma (p > 0.05). In con-
trast, in animals that were treated with 50 mg/kg ABZ,
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Combination therapy with 50 mg/kg ABZ and 2ME,
had no effect on VEGF levels in comparison with vehicle
(p > 0.05). However, a significant reduction in VEGF level
was observed in the mice that received the combination of
25 mg/kg ABZ with 2ME compared with vehicle-treated
group (p = 0.0016), and animals which were treated with
ABZ and 2ME as single agents (p = 0.01 and p = 0.0025,
respectively).
Discussion
One of the main approaches in cancer therapy is to utilize
the combination of chemotherapeutic agents with the ob-
jective of improving efficacy while maintaining the overall
toxicity to an acceptable level. As a single agent, ABZ has
been shown to be a promising anticancer agent both
in vitro and in vivo. Nevertheless, its combination with
other cytotoxic agents may further improve its application.
Given the proven success of MTAs such as vinca alkaloids
and taxanes in cancer therapy and the fact that MTAs can
synergize with one another, the combination of ABZ with
PTX, VBL, and CLC was evaluated.
In both HCT-116 and DU145 cell lines, the combination
of ABZ with PTX resulted in antagonism throughout the
PTX concentrations used. Likewise, VBL had an antagon-
istic interaction with ABZ regardless of the concentration
tested. Surprisingly, a dose-dependent synergistic inter-
action between ABZ and CLC was observed. CLC is not
being used in cancer treatment despite its effectiveness.
Therefore, the interaction between ABZ with 2ME was
evaluated. 2ME has been shown to be active against aFigure 5 Effect of ABZ, 2ME, and their combination on inhibition of t
subcutaneous tumor. Ki67-positive cells (brown) were counted and repor
phases in each field. CD31-positive vessel area (brown) were measured per
counted and reported as the percentage of total cells. (1) Vehicle control, (
ABZ plus 2ME, and (6) 50 mg/kg ABZ plus 2ME. (*P < 0.05 and **P < 0.001 cvariety of cancer cells both in vitro and in vivo and more
importantly, it does not exhibit myelosupression and other
hematological toxicities associated with MTAs [15]. This
property makes 2ME an ideal candidate for the combin-
ation with other MTAs, as overlapping toxicities being the
major limiting factor in combination therapies would be
greatly diminished. It was hypothesized that since 2ME
shares the same binding site on β-tubulin as CLC, and its
structure and mechanism of action are similar to CLC, it
may act synergistically with ABZ.
Similar to CLC, 2ME exhibited a dose- and schedule-
dependent synergistic interaction with ABZ in inhibiting
the proliferation of HCT-116 and DU145 cells. While
simultaneous treatment with ABZ and 2ME resulted in
the most synergistic interactions compared with other
schedules, pre-incubation with 2ME led to antagonism
in all tested concentrations.
Synergism between MTAs has been reported previously.
For example, paclitaxel can act synergistically with vinblast-
ine [11], and estramustine [16]. Estramustin plus vinblastine
[17,18], and vinorelbine plus docetaxel [19] are more effect-
ive than either drug alone, and vinorelbine plus paclitaxel
[20], and docetaxel plus CI-980 [21], are superior to single
agents. Yet, it is uncommon for two agents to interact syn-
ergistically while they bind to the same binding site. More
often, this kind of combination leads to additivity or antag-
onism, as the drugs cannot bind to the same site simultan-
eously. The only exception reported, is a study by Martello
et. al., demonstrating that taxol and discodermolide repre-
sented a synergistic drug combination in four human can-
cer cell lines [22] and a subsequent study showed that taxolumor cell proliferation, angiogenesis, and apoptosis in HCT-116
ted as the percentage of the total number of cells in proliferative
high-power field (103 pixels). Cells underwent apoptosis (brown) were
2) 25 mg/kg ABZ, (3) 50 mg/kg ABZ, (4) 25 mg/kg 2ME, (5) 25 mg/kg
ompared with single agents).
Ehteda et al. BMC Cancer 2013, 13:86 Page 10 of 13
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tubule dynamics [23].
Several studies have reported that benzimidazoles bind
to the colchicine-binding site of mammalian tubulin
[7,8,24,25]. In contrast, a recent study suggested that
benomyl, an antifungal agent and a member of benz-
imidazole compounds, did not inhibit the binding of
colchicine to its binding site [26] and in a subsequent
study, the combination of benomyl and colchicine was
shown to be synergistic [27]. Due to these conflicting
data, we investigated the interactions between 2ME
plus CLC, and combretastatin A4 (CA4) plus CLC. In
addition, the combination of these three colchicine-
binding agents with one another was also evaluated (data
not shown). It was hypothesized that antagonism be-
tween colchicine-binding agents would further confirm
that ABZ does not bind to the colchicine-binding site.
Surprisingly, we found that all four tested colchicine-
domain binders represented a concentration-dependentFigure 6 Effect of ABZ, 2ME and combination on VEGF levels in tumo
were analyzed for VEGF levels and the blot is representative of four sample
shows densitometric analysis of VEGF immunoblot and each column repre
cardiac puncture and plasma samples were subjected to ELISA assay for VE
(**P < 0.001 compared with single agents).synergistic cytotoxic effect on the proliferation of HCT-
116 and DU-145 cell lines.
It is well known that at clinically relevant doses, both
microtubule-polymerizing and microtubule-depolymerizing
compounds suppress the dynamics of microtubule without
affecting the microtubule polymer mass. For instance, the
IC50 values for inhibiting the cell proliferation by 2ME
is 10- to 100-fold lower than the concentration required
for tubulin depolymerization [28]. As for ABZ, in 1A9 ovar-
ian cancer cells the concentration required for tubulin
depolymerization, is 10-fold higher than the IC50 values for
inhibiting cell growth [29]. These results suggest that there
is only a modest correlation between the concentrations
that induce cell death and the concentrations that affect
microtubule polymer mass. Similar to ABZ and 2ME, it has
been shown that at low concentrations, CLC suppresses the
dynamic instability of microtubules with no effect on the
polymer mass [30]. As a result, while the stoichiometry of
CLC binding to soluble tubulin is approximately 1 mol perr and plasma sample. A, Four tumors from each treatment group
s. β-actin was used as a control for equal protein loading. Graph
sents the mean ± SEM. B, Following euthanasia, blood was collected by
GF levels. Each column represents mean VEGF levels ± SEM (n = 8–9).
Ehteda et al. BMC Cancer 2013, 13:86 Page 11 of 13
http://www.biomedcentral.com/1471-2407/13/86mol tubulin [31] much less CLC with very little binding is
required to inhibit the dynamic instability of microtubules
[32]. Considering that each micrometer of microtubule
contains 1690 tubulin dimers, a great number of binding
sites are available for the drug molecules [9,33]. Therefore,
it is conceivable that additional drugs could be bound
to microtubules.
Another explanation is that the drugs may exhibit differ-
ent affinity towards different isotypes of tubulin [34]. In
mammals, six isotypes of α-tubulin and seven isotypes of
β-tubulin have been recognized [35]. CLC has been
proven to have the highest affinity for αβIV and the lowest
affinity for αβIII [36]. Unfortunately, there is no published
data on the binding affinities of ABZ and 2ME to various
tubulin isotypes. Nevertheless, if the drugs discriminate
among the various isotypes or among various forms of mi-
crotubules and the preference of each drug in terms of
binding to a specific isotype of tubulin differs from the
other drug, then it is plausible to conclude that the syn-
ergy may result from different affinity of the drugs towards
different forms or isotypes of microtubules [34].
The mechanism of synergism between ABZ and 2ME
was next explored by evaluating the effects of the combin-
ation therapy on tubulin polymerization and apoptosis-
related proteins. As expected, comparison between the per-
centage of polymerized tubulin in the cells that were
treated with the single agents and with the combination
revealed that the concentrations at which synergistic
anti-proliferative effect were observed, did not induce
depolymerization of tubulin. These results imply that the
effect of the combination of ABZ and 2ME on cell prolifer-
ation and their synergistic interaction is not mediated
through the inhibition of tubulin polymerization. In this
regard, it remains to be established whether the suppres-
sion of microtubule dynamics account for this synergistic
interaction.
Activation of caspase cascade has been proven to be the
central mechanism promoting apoptosis in response to
chemotherapy. Therefore, to elucidate whether the cell
death induced by ABZ and 2ME is mediated through
apoptosis, the activity of caspase-3, caspase-8 and caspase-
9 were assessed. Two major apoptosis pathways, the ex-
trinsic pathway and the intrinsic pathway converge on
caspases activation [37]. The extrinsic pathway is activated
through the death receptors (DRs). Interaction of DRs
with tumor necrosis factor-related apoptosis–inducing lig-
and (TRAIL) induces the activation caspase-8, which in
turn, triggers the cascade of activated procapases that fol-
lows [37-39]. The intrinsic pathway is controlled by Bcl-2
family of proteins and involves the release of apoptosome
containing caspase 9 [38]. Activation of initiator caspase-8
and −9 result in the cleavage of caspase-3 [40,41]. Results
from caspase activity assay revealed that while both single
agent treatment and combination therapy failed to activatecaspase-9, they activated caspase-8 and caspase-3 in a time-
dependent manner. Additionally, combination therapy was
significantly more effective in the activating caspase-8 and
caspase-3 in comparison with single drug treatment. The
expression of DR5 was also induced in the cells that were
treated with both single agents and the combination of the
drugs, with combination treatment producing a more pro-
nounced effect. These results suggest that the extrinsic
death receptor apoptotic pathway is involved in drug-
induced apoptosis in HCT-116 cells. The mechanism of
upregulation of DR5 is not clear but most likely is inde-
pendent form p53, as no increase in the protein levels of
P53 was observed. DR5 has been shown to be activated in
both ligand-dependent and ligand-independent manner.
While p53 has been implicated in ligand-independent
upregulation of DR5 [42], it is not required for the apop-
totic response to TRAIL [43]. Possible role of TRAIL in
DR5 overexpression and the upstream signal that lies
between drug exposure and activation of caspases are
unknown.
Historically, MTAs-induced apoptosis is mediated pri-
marily by the mitochondria/caspase 9 activation pathway.
Yet, it has been reported that the extrinsic pathway may
also be engaged by MTAs. For instance, PTX has been
shown to up-regulate DR5 protein and sensitizes prostate
cancer cell lines to the cytotoxic effects of TRAIL [44].
However, these effects appear to be cell line-dependent, as
they were not observed in non-small cell lung and breast
cancer cell lines [45,46]. In agreement with current results,
2ME has also been reported to overexpress DR5 in a var-
iety of human cancer cell lines including breast, cervical,
prostate and glioma cells [47].
In our in vivo pilot study, concurrent administration of
ABZ and 2ME resulted in an acute toxicity in the animals.
Signs of toxicity were convulsion and haematuria which
were also observed when the mice received the combin-
ation of the drug-free vehicles. This toxicity was at least in
part, due to the high concentrations of HPβCD, as the
LD50 of HPβCD in mice is 10 g/kg, while the combination
of the vehicles contained nearly 12 g/kg HPβCD. There-
fore, in the subsequent study, ABZ and 2ME were admin-
istered sequentially with ABZ preceding 2ME. Although
this schedule showed no toxicity to the animals, it may
have compromised the antitumor efficacy, as the results
from in vitro drug interaction analysis suggested that sim-
ultaneous treatment with ABZ and 2ME was the most ef-
fective schedule.
Evaluating the combination therapy in mice-bearing
HCT-116 tumors indicated that 50 mg/kg ABZ as a sin-
gle agent was more effective in prolonging the survival
of animals compared with combination therapy. These
results were consistent with the in vitro assay where the
combination of high concentrations of ABZ with 2ME
represented an antagonistic anti-proliferative effect on
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ABZ (25 mg/kg) with 2ME significantly prolonged the
survival of mice compared with treatment with single
agents. In addition, combination therapy significantly
suppressed tumor cell proliferation compared with treat-
ment with single agents. Further, analysis of tumor sam-
ples from these mice revealed that the combination
therapy significantly decreased microvessel density and
markedly increased the number of apoptotic tumor cells.
Finally, tumor and plasma of mice that were treated with
the combination of ABZ and 2ME had a significantly
lower VEGF levels in comparison with the animals that
received single agents or vehicle.
Conclusion
This study shows that the combination of low dose of ABZ
and 2ME represent a synergistic anti-tumor effect. High ef-
fectiveness of the combination therapy stemmed from the
inhibition of the proliferation of tumor cells, suppression of
angiogenesis, and induction of apoptosis. The finding that
the combination of two colchicine-domain binders can act
synergistically, suggests that such drug combinations, which
would not normally be considered due to the similar mech-
anism of action and identical binding sites may nevertheless
provide therapeutic benefit in cancer therapy.
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